ARCA biopharma Company Profile (NASDAQ:ABIO)

About ARCA biopharma

ARCA biopharma logoARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ABIO
  • CUSIP:
Key Metrics:
  • Previous Close: $2.55
  • 50 Day Moving Average: $2.63
  • 200 Day Moving Average: $2.64
  • 52-Week Range: $2.15 - $4.35
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.14
  • P/E Growth: 0.00
  • Market Cap: $23.16M
  • Outstanding Shares: 9,082,000
  • Beta: 2.16
Profitability:
  • Return on Equity: -47.28%
  • Return on Assets: -44.61%
Debt:
  • Current Ratio: 11.06%
  • Quick Ratio: 11.06%
Additional Links:
Companies Related to ARCA biopharma:

Analyst Ratings

Consensus Ratings for ARCA biopharma (NASDAQ:ABIO) (?)
Ratings Breakdown: 2 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $4.00 (56.86% upside)

Analysts' Ratings History for ARCA biopharma (NASDAQ:ABIO)
Show:
DateFirmActionRatingPrice TargetDetails
2/23/2016Royal Bank Of CanadaReiterated RatingSector Perform$5.00 -> $4.00View Rating Details
2/23/2016Cowen and CompanyReiterated RatingMarket Perform$5.50 -> $4.00View Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for ARCA biopharma (NASDAQ:ABIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2017        
11/21/2014($0.15)($0.11)ViewN/AView Earnings Details
8/19/2014($0.13)($0.11)ViewN/AView Earnings Details
5/29/2014($0.12)($0.13)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ARCA biopharma (NASDAQ:ABIO)
Current Year EPS Consensus Estimate: $-1.75 EPS
Next Year EPS Consensus Estimate: $-1.19 EPS

Dividends

Dividend History for ARCA biopharma (NASDAQ:ABIO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ARCA biopharma (NASDAQ:ABIO)
Insider Ownership Percentage: 2.46%
Institutional Ownership Percentage: 50.54%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/18/2016Thomas A. KeuerCOOSell483$2.45$1,183.35View SEC Filing  
9/20/2016Christopher David OzeroffVPSell1,185$2.89$3,424.65View SEC Filing  
9/20/2016Michael R. BristowInsiderSell1,972$2.89$5,699.08View SEC Filing  
9/20/2016Thomas A. KeuerCOOSell714$2.89$2,063.46View SEC Filing  
9/19/2016Brian L. SelbyVPSell476$2.91$1,385.16View SEC Filing  
4/5/2016Christopher David OzeroffVPSell366$3.52$1,288.32View SEC Filing  
4/5/2016Michael R BristowInsiderSell724$3.52$2,548.48View SEC Filing  
4/5/2016Thomas A KeuerCOOSell384$3.52$1,351.68View SEC Filing  
4/4/2016Brian L SelbyVPSell1,114$3.52$3,921.28View SEC Filing  
3/1/2016Christopher David OzeroffVPSell458$3.51$1,607.58View SEC Filing  
3/1/2016Michael R. BristowInsiderSell752$3.50$2,632.00View SEC Filing  
3/1/2016Thomas A. KeuerCOOSell457$3.53$1,613.21View SEC Filing  
9/18/2015Christopher David OzeroffVPSell1,129$6.32$7,135.28View SEC Filing  
3/2/2015Brian L SelbyVPSell1,125$0.71$798.75View SEC Filing  
3/2/2015Michael R BristowInsiderSell5,446$0.71$3,866.66View SEC Filing  
1/16/2015Riley MccormackMajor ShareholderSell350,000$0.76$266,000.00View SEC Filing  
1/7/2015Riley MccormackMajor ShareholderSell550,000$0.92$506,000.00View SEC Filing  
9/18/2014Michael R BristowCEOSell13,853$1.30$18,008.90View SEC Filing  
9/18/2014Patrick M WheelerCFOSell8,246$1.31$10,802.26View SEC Filing  
2/4/2014Riley MccormackMajor ShareholderBuy1,000,000$1.70$1,700,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for ARCA biopharma (NASDAQ:ABIO)
DateHeadline
thestreet.com logoAnders Hove, M.D. (Photo: Business Wire) (NASDAQ:ABIO)
www.thestreet.com - February 21 at 3:32 PM
4-traders.com logoARCA BIOPHARMA, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) (NASDAQ:ABIO)
www.4-traders.com - February 21 at 3:32 PM
finance.yahoo.com logoAnders Hove, MD Joins ARCA biopharma Board of Directors (NASDAQ:ABIO)
finance.yahoo.com - February 21 at 3:32 PM
biz.yahoo.com logoARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits (NASDAQ:ABIO)
biz.yahoo.com - February 21 at 3:32 PM
finance.yahoo.com logoARCA biopharma Announces 150th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial (NASDAQ:ABIO)
finance.yahoo.com - January 18 at 3:39 PM
News IconARCA biopharma Inc ABIO Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:ABIO)
www.bioportfolio.com - January 16 at 3:17 PM
biz.yahoo.com logoARCA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibit (NASDAQ:ABIO)
biz.yahoo.com - January 11 at 8:17 PM
finance.yahoo.com logoARCA biopharma to Present at Biotech Showcase 2017 (NASDAQ:ABIO)
finance.yahoo.com - January 4 at 3:17 PM
insidermonkey.com logoHedge Funds Aren’t Crazy About A. M. Castle & Co (CASL) Anymore (NASDAQ:ABIO)
www.insidermonkey.com - December 20 at 3:07 PM
News IconARCA biopharma, Inc. formerly Nuvelo, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 (NASDAQ:ABIO)
www.bioportfolio.com - November 28 at 2:41 PM
News IconARCA biopharma, Inc. ABIO Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:ABIO)
www.bioportfolio.com - November 22 at 8:48 PM
News IconARCA biopharma, Inc. ABIO Financial and Strategic SWOT Analysis Review Prices from USD $300 (NASDAQ:ABIO)
www.bioportfolio.com - November 17 at 8:29 PM
finance.yahoo.com logoStockNewsNow.com Publishes New SNNLive Video Interview with ARCA biopharma, Inc. Provides Company Overview and Discusses Clinical Development (NASDAQ:ABIO)
finance.yahoo.com - November 15 at 12:32 PM
4-traders.com logoARCA BIOPHARMA, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) (NASDAQ:ABIO)
www.4-traders.com - November 14 at 8:55 PM
businesswire.com logoARCA biopharma Announces Third Quarter 2016 Financial Results and Provides Business Update (NASDAQ:ABIO)
www.businesswire.com - November 14 at 8:55 PM
reuters.com logoBRIEF-Arca Biopharma Q3 loss per share $0.51 (NASDAQ:ABIO)
www.reuters.com - November 14 at 8:55 PM
thestreet.com logoDr. Michael R. Bristow, President And CEO, ARCA Biopharma, Inc. (NASDAQ:ABIO)
www.thestreet.com - October 7 at 8:02 AM
publicnow.com logoARCA biopharma Announces Randomization of First European Patients in GENETIC-AF Phase 2B/3 Clinical Trial (NASDAQ:ABIO)
www.publicnow.com - October 6 at 3:14 PM
finance.yahoo.com logoARCA biopharma to Present at the Dawson James Securities Second Annual Growth Stock Conference (NASDAQ:ABIO)
finance.yahoo.com - October 4 at 3:15 PM
4-traders.com logoARCA Biopharma : Assigned Patent (NASDAQ:ABIO)
www.4-traders.com - September 22 at 3:15 PM
finance.yahoo.com logoARCA biopharma Named Winner of Corporate LiveWire Healthcare and Lifesciences Innovation Award (NASDAQ:ABIO)
finance.yahoo.com - September 13 at 3:15 PM
rttnews.com logoEARS Faces The Music, ABIO On Track, TEVA Gets EU Nod For Asthma Drug (NASDAQ:ABIO)
www.rttnews.com - August 19 at 11:29 AM
4-traders.com logoARCA BIOPHARMA, INC. : Other Events, Financial Statements and Exhibits (form 8-K) (NASDAQ:ABIO)
www.4-traders.com - August 18 at 8:39 PM
reuters.com logoBRIEF-Arca says 100th patient randomized into the genetic-AF phase 2b/3 clinical trial (NASDAQ:ABIO)
www.reuters.com - August 18 at 3:15 PM
publicnow.com logoARCA biopharma Announces 100th Patient Randomized into the Genetic-AF Phase 2B/3 Clinical Trial (NASDAQ:ABIO)
www.publicnow.com - August 18 at 11:39 AM
4-traders.com logoARCA biopharma : Announces Second Quarter 2016 Financial Results and Provides Business Update (NASDAQ:ABIO)
www.4-traders.com - August 9 at 8:50 PM
publicnow.com logoARCA biopharma Announces Second Quarter 2016 Financial Results and Provides Business Update (NASDAQ:ABIO)
www.publicnow.com - August 9 at 8:50 PM
capitalcube.com logoAlbioma :ABIO-FR: Earnings Analysis: For the six months ended June 30, 2016 : August 3, 2016 (NASDAQ:ABIO)
www.capitalcube.com - August 3 at 11:48 AM
streetinsider.com logoForm 4 ARCA biopharma, Inc. For: Jun 09 Filed by: Selby Brian L. (NASDAQ:ABIO)
www.streetinsider.com - June 15 at 3:16 PM
4-traders.com logoARCA BIOPHARMA, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K) (NASDAQ:ABIO)
www.4-traders.com - June 15 at 3:16 PM
biz.yahoo.com logoARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote o (NASDAQ:ABIO)
biz.yahoo.com - June 13 at 5:01 PM
businesswire.com logoARCA biopharma Announces First Quarter 2016 Financial Results and Provides Business Update - Business Wire (press release) (NASDAQ:ABIO)
www.businesswire.com - May 12 at 9:47 AM
publicnow.com logoARCA biopharma Announces First Quarter 2016 Financial Results and Provides Business Update (NASDAQ:ABIO)
www.publicnow.com - May 11 at 7:07 PM
biz.yahoo.com logoARCA BIOPHARMA, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:ABIO)
biz.yahoo.com - May 11 at 4:49 PM
kcregister.com logoInvestors Watch List: ARCA biopharma, Inc. (NASDAQ:ABIO), Idera Pharmaceuticals (NASDAQ:IDRA), EverBank ... - KC Register (NASDAQ:ABIO)
www.kcregister.com - April 26 at 10:20 AM
News IconPipeline of congestive heart failure (heart failure) market H1 2016published by leading research firm (NASDAQ:ABIO)
www.whatech.com - April 26 at 10:20 AM
biz.yahoo.com logoARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:ABIO)
biz.yahoo.com - April 18 at 4:31 PM
businesswire.com logoARCA biopharma Announces 75th Patient Enrolled in GENETIC-AF Phase 2B/3 Clinical Trial - Business Wire (press release) (NASDAQ:ABIO)
www.businesswire.com - April 18 at 10:27 AM
finance.yahoo.com logoARCA biopharma Announces 75th Patient Enrolled in GENETIC-AF Phase 2B/3 Clinical Trial (NASDAQ:ABIO)
finance.yahoo.com - April 18 at 9:00 AM
News IconArca Biopharma Incorporated (NASDAQ:ABIO) Shorted Shares Decreased By 10.89% - Stock Caller (NASDAQ:ABIO)
www.stockcaller.com - April 15 at 1:22 PM
News IconRa Capital Management Lowers stake in Arca Biopharma Inc (ABIO) - The Sussex Pilot (NASDAQ:ABIO)
sussexpilot.com - April 8 at 1:29 PM
News IconWatch for Action: BGC Partners (NASDAQ:BGCP), ARCA biopharma (NASDAQ:ABIO), Vale S.A. (NYSE:VALE ... - Property Mentor (NASDAQ:ABIO)
www.propertymentorgroup.com - April 7 at 1:48 PM
News IconArca Biopharma, Inc. (ABIO) Files Form 4 Insider Selling : Thomas A Keuer Sells 384 Shares - SCSUCollegian (NASDAQ:ABIO)
www.thescsucollegian.com - April 7 at 1:48 PM
News IconArray Bio ends late-stage study of ovarian cancer drug - ETHealthWorld.com (NASDAQ:ABIO)
health.economictimes.indiatimes.com - April 2 at 1:30 PM
finance.yahoo.com logoARCA BIOPHARMA, INC. Financials (NASDAQ:ABIO)
finance.yahoo.com - March 23 at 1:04 PM
biz.yahoo.com logoARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi (NASDAQ:ABIO)
biz.yahoo.com - March 17 at 4:44 PM
finance.yahoo.com logoGENETIC-AF Clinical Trial for Prevention of Atrial Fibrillation Enrolls 50th Patient (NASDAQ:ABIO)
finance.yahoo.com - January 12 at 8:30 AM
finance.yahoo.com logoApplying Lessons from KBIO (NASDAQ:ABIO)
finance.yahoo.com - December 8 at 9:00 AM
finance.yahoo.com logo2 Micro-Cap Opportunities in Atrial Fibrillation (NASDAQ:ABIO)
finance.yahoo.com - November 30 at 9:38 AM
finance.yahoo.com logoBiotechs Under 20 Dollars Poised to Breakout (NASDAQ:ABIO)
finance.yahoo.com - November 23 at 3:07 PM

Social

What is ARCA biopharma's stock symbol?

ARCA biopharma trades on the NASDAQ under the ticker symbol "ABIO."

Where is ARCA biopharma's stock going? Where will ARCA biopharma's stock price be in 2017?

2 brokerages have issued 12-month price objectives for ARCA biopharma's shares. Their forecasts range from $4.00 to $4.00. On average, they expect ARCA biopharma's stock price to reach $4.00 in the next twelve months.

When will ARCA biopharma announce their earnings?

ARCA biopharma is scheduled to release their next quarterly earnings announcement on Wednesday, March, 15th 2017.

How do I buy ARCA biopharma stock?

Shares of ARCA biopharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of ARCA biopharma stock cost?

One share of ARCA biopharma stock can currently be purchased for approximately $2.55.

ARCA biopharma (NASDAQ:ABIO) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for ARCA biopharma (NASDAQ:ABIO)

Earnings History Chart

Earnings by Quarter for ARCA biopharma (NASDAQ:ABIO)

Dividend History Chart

Dividend Payments by Quarter for ARCA biopharma (NASDAQ:ABIO)

Last Updated on 2/23/2017 by MarketBeat.com Staff